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AbstrAct
Objectives To assess social stigmatisation related to 
atypical appearance of the body, including, but not limited 
to the external genitalia, among Indonesian patients 
with a disorder of sex development (DSD). Until recently, 
diagnostic evaluation, information about the underlying 
causes of DSD and treatment options were sparsely 
available for these patients.
Methods Eighty-one parents of children and 
adolescents with DSD (aged 6–17 years) and 34 adult 
patients with DSD (aged 18–41 years) completed the 
Social Stigmatisation Scale towards DSD, an instrument 
developed to assesses the frequency of stigmatisation 
and the level of stress associated with these experiences. 
Open-ended questions investigated detailed information 
on stigmatisation as well as parents’ and patients’ 
emotional and behavioural reactions to these experiences. 
Differences in stigmatisation were explored across sex of 
rearing, gender change history, treatment status and DSD 
characteristics that could be easily identified by others 
(e.g., masculinisation of the body in women).
results Social stigmatisation was reported by patients 
with atypical appearance of their genitalia, atypical 
appearance of their body aside from their genitals, 
among those who displayed cross-gender behaviour and 
those who changed gender. Among participants reared 
as women and among children and adolescents who 
changed gender, social stigmatisation was associated with 
ostracism, depressive symptoms and social isolation.
conclusions Patients unable to conceal their condition 
(those with visible physical atypicality and those who 
changed gender) experienced social stigmatisation. 
Stigmatisation was stressful and related to isolation and 
withdrawal from social interaction. Education about DSD, 
self-empowerment and medical interventions to prevent 
atypical physical development may remove barriers to 
acceptance by others for affected individuals.
IntrOductIOn
Disorders of sex development (DSD) refer 
to a group of congenital conditions in which 
development of chromosomal, gonadal or 
anatomical sex is atypical, often leading to 
an atypical appearance of the genitals and 
other parts of the body that differ in appear-
ance between men and women.1 Clinicians 
specialised in DSD treatment are confronted 
with parents’ and patients’ difficulties in 
coping with the atypical physical develop-
ment and the derogatory reactions their atyp-
icality may elicit. In addition to treatments 
necessary for survival, clinical management 
aims to reduce or prevent physical atypicality 
and to enable sexual functioning in order to 
increase the patient’s opportunities for social 
participation. These interventions have been 
criticised, as they impact the child’s life and 
are often performed without the child’s assent 
or consent. It has been argued that such 
interventions do not allow for diversity in sex 
and gender development and are principally 
conducted to comfort parents or support 
the gender ideology of society.2–6 As such, 
there have been calls to stop this practice of 
What this study hopes to add?
 ► We developed the Social Stigmatisation Scale for 
disorder of sex development (DSD) and investigated 
patients’ and parents’ experienced stigma.
 ► Experienced and anticipated DSD-related 
stigmatisation was highest among patients with 
body atypicality and patients who changed gender.
 ► Social stigmatisation was evaluated as stressful, 
related to (self)isolation and highly correlated with 
depression.
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Original article
What is already known on this topic?
 ► Disorder of sex development (DSD) is a somatically 
and socially challenging condition; many patients 
and parents suffer from emotional problems, 
experience or anticipate social stigmatisation.
 ► Opposing opinions rule the debate on how to 
strengthen patients’ emotional well-being and 
improve their psychosocial opportunities.
 ► At present DSD-associated social stigma has not 
been investigated systematically. Such studies are 
necessary in order to make proper adjustments in 
clinical management.
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Table 1 Disorder of sex development (DSD) diagnoses of participants in the study (n=115)
DSD diagnosis
Age
6–11 12–17 18+ Total
Sex chromosome DSD Patients with 45, X/46, XY; 
46, XidicY; 46, XX/46, XY;
46, XX/47, XXY
6 3 5 14
46, XY DSD AIS* 5 5 6 16
Gonadal dysgenesis† 6 2 10 18
Hypomasculinisation‡ 25 9 7 41
46, XX DSD CAH-SV§ 18 2 4 24
Gonadal dysgenesis† – – 1 1
Cloacal malformation – – 1 1
Total 60 21 34 115
*Androgen insensitivity syndrome. Androgen receptor gene mutation was confirmed.26
†Abnormal hormonal testicular function with unilaterally/bilaterally undescended testes. The clinical and biochemical presentation suggest 
gonadal dysfunction. Serum levels of luteinising hormone and follicle stimulating hormone were elevated but testosterone, anti-Müllerian 
hormone and inhibin are low for age, and no or diminished serum testosterone response to human chorionic gonadotropin.
‡46, XY karyotype with hypomasculinisation of unknown cause, despite extensive analysis.26
§Congenital adrenal hyperplasia simple virilising type. CYP 21 mutation was confirmed.26
Details on diagnosis and degree of masculinisation at admission per patient can be found in Ediati et al.14 24
medical and surgical intervention.7–9 However, there is a 
lack of systematic data on DSD-associated stigma among 
affected individuals who did not receive such interven-
tions.2 Randomised controlled studies of early gender 
assignment, genital surgery and hormonal interventions 
compared with delayed interventions are highly valued10 
but difficult to conduct. Despite criticisms noted above, 
most parents living in Western countries choose early 
gender assignment and surgical correction of the atyp-
ical genitalia for their children with DSD.11 12 Follow-up 
studies on quality of life are scarce and findings are 
inconsistent regarding the risks and benefits of medical 
intervention.13–15 Finally, the medical literature contains 
few reports on DSD and social stigmatisation.16–23 
In Indonesia, DSD is not widely known among health 
practitioners and laymen. Clinical management is chal-
lenged by limited diagnostic and treatment facilities. As 
a result, many patients live with atypical bodies and expe-
rience doubts about their gender.24 25 During outpatient 
clinic visits, experiences with social stigmatisation were 
often reported spontaneously by these patients and stim-
ulated many patients and parents to seek medical help. 
This enabled us to investigate these patients’ experi-
ences of living with physical ambiguity and doubts about 
their gender,24 25 as well as their experience of social 
stigmatisation.
MethOds
study design and setting
Experiences with social stigmatisation due to DSD were 
evaluated from adult patients and parents of affected 
children and adolescents. Data collection were carried 
out between March 2007 and May 2011. All patients 
consulted the DSD Team of the Dr. Kariadi Hospital. The 
study protocol was approved by the board of the ethical 
committee at the Faculty of Medicine, Diponegoro 
University, Semarang, Indonesia.
Patients
All patients with a confirmed diagnosis of DSD consulting 
the DSD Team of the Dr. Kariadi Hospital26 were invited 
to participate in the study. Patients and parents received 
oral and written study information (provided by AZJ).
All participating patients and parents provided informed 
consent. Patients with a genital anomaly and additional 
features suggestive of a dysmorphic syndrome,27 patients 
with sex chromosome DSD without mosaicism and 
patients with DSD and intellectual disabilities (indicated 
from the child’s academic achievements and/or observed 
by the medical doctor in interaction with the patient) 
were excluded. Thirty-four adults (20 men; 14 women; 
aged 18–41 years) and 81 parents of 60 children (42 boys, 
18 girls; aged 6–11) and 21 adolescents (15 boys; 6 girls; 
aged 12–17 years) participated, with a participation rate 
of 78%. Table 1 summarises patient characteristics and 
diagnoses.
Procedure
After obtaining written, informed consent, psychological 
assessment including data on patients’ socioeconomic 
and ethnic-cultural background14 24 25 was collected in the 
hospital or at the patient’s home, by a trained psycholo-
gist (AE).
Materials
Prior to this study, no measure was available to assess social 
stigmatisation in patients with DSD. Therefore, we devel-
oped the Social Stigmatisation Scale for DSD (SSS-DSD). 
The SSS-DSD assesses the frequency of experienced 
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stigmatisation (1–13a questions) and the level of stress 
evoked by the stigmatising experiences (1–13b questions) 
using a Likert scale with responses ranging from ‘not at 
all’1 to ‘very much’.5 In addition, we asked patients to give 
details about their experiences with DSD, their beliefs on 
the cause of their DSD, their concerns and ability to cope 
with DSD (1–12c questions). We developed parent and 
adult versions of the SSS-DSD.
The applicability of the SSS-DSD was tested (by AE) 
prior to implementation and revealed that applying the 
measure as a paper–pencil test was feasible for well-ed-
ucated subjects. The rating scale was piloted in a small 
group of 20 patients and parents with DSD. After a few 
adaptations, the SSS-DSD seemed suitable for application 
in this study. Formal large scale psychometric pretesting 
among sizeable numbers of patients or their parents was 
considered unfeasible in view of the limited numbers 
of patients with rare genetic conditions. For parents 
and patients who could not read well, the measure was 
applied verbally.
data analysis
Construct validity of both the adult and parental versions 
of the SSS-DSD scale was explored using principal compo-
nent analysis (PCA) with varimax rotation and Kaiser 
normalisation method. Factors with eigenvalues greater 
than 1 and items with factor loadings (after rotation) 
greater than 0.40 were considered acceptable. The relia-
bility of the instrument was evaluated using Cronbach’s α 
as a measure of internal consistency.
The overall and domain sum scores of the SSS-DSD 
were calculated as the unweighted sum scores of the indi-
vidual domains and items, respectively. For all sum scores, 
a higher score indicates a relatively higher level of stigma, 
atypicality, social exclusion and emotional problems. 
With Spearman’s correlation coefficient (r) the correla-
tions between different types of stigma and evoked stress 
were evaluated. The Kruskal-Wallis test was applied to 
test for differences in continuous data of more than two 
groups, the Mann-Whitney U test for differences between 
two independent groups. Differences in categorical data 
were compared using Fisher’s exact test. Differences were 
considered significant at p<0.05 (two-sided).
Qualitative data collected were analysed by inductive 
content analyses using NVivo qualitative data analysis 
software.28 29 AE started an open coding procedure and 
finally clustered codes into four themes. Relationships 
between themes were investigated using the compound 
coding application in NVivo.28 29
results
The majority of participants were men, lived in rural 
areas, Javanese and Muslim. Parents’ educational back-
grounds varied from no formal education to university 
level, and the majority attended high school and worked 
in the lower-income sector or were unemployed. Details 
on socioeconomic and ethnic-cultural variables can be 
found in table 2.
reliability and validity of sss-dsd parent and adult versions
SSS-DSD parent
The PCA extracted four components with Cronbach’s 
α ranging between 0.84 and 0.88. Reliability (internal 
consistency) of the parent version can be considered as 
good. The four components explaining 56% of the total 
variance were as follows: (1) stigmatisation elicited by 
genital ambiguity (items 1–2, 5–6, 11; α=0.86); (2) stig-
matisation elicited by atypical physical appearance or 
cross-gender role behaviour (items 3–4, 7–8a; α=0.84); 
(3) social exclusion (items 9–10, 12; α=0.88) and (4) 
emotional problems due to DSD (items 13a–d, 13g–h; 
α=0.85). Table 3A shows the factor loadings after varimax 
rotation and the Cronbach’s α of each component. The 
construct validity of the SSS-DSD parent was considered 
satisfactory.
SSS-DSD adult
The PCA extracted three components with Cronbach’s 
α ranging between 0.85 and 0.94. Reliability (internal 
consistency) of the Adult version was considered as 
good to very good. The extracted three components 
explaining 62.9% of the total variance were as follows: 
(1)verbal stigmatisation (items 1–2, 4–5, 7; α=0.92); (2) 
behavioural stigmatisation (items 3, 6a, 9–10; α=0.85) 
and (3) emotional problems due to DSD (items 13–15; 
α=0.94). Table 3B shows the factor loadings after varimax 
rotation and the Cronbach’s α of each component. The 
construct validity of the SSS-DSD adult was also consid-
ered satisfactory.
correlations between stigmatisation and stress
In both measures, items measuring experiences with stig-
matisation were positively and significantly correlated 
with items measuring stress evoked by such stigmatisa-
tion, in all components measured.
SSS-DSD parent
Stigmatisation due to genital ambiguity positively corre-
lated with stress (r
s
 (79)=0.794, p<0.001); stigmatisation 
elicited by an ambiguous appearance or behaviour posi-
tively correlated with stress (r
s
(79)=0.80, p<0.001); social 
rejection positively correlated with stress (r
s
(79)=0.81, 
p<0.001) and emotional problems also positively corre-
lated with stress (r
s
(79)=0.64, p<0.001).
SSS-DSD adult
Verbal stigmatisation positively correlated with stress 
(r
s
(32)=0.755, p<0.001); behavioural stigmatisation posi-
tively correlated with stress (r
s
(32)=0.753, p<0.001) and 
emotional and acceptance problems due to DSD also 
positively correlated with stress (r
s
(32)=0.882, p<0.001). 
The more frequently patients experienced social stigma-
tisation, the higher their reported stress.
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Table 2 Participant characteristics (N=115)
Characteristics
Children and 
adolescents (n=81)
Adults 
(n=34)
Gender (of patients)
  Male 57 (70) 20 (59)
  Female 24 (30) 14 (41)
Treatment
  Received treatment* 44 (54) 15 (44)
  No treatment 37 (46) 19 (56)
Social gender role change†
  Yes 7 (9) 15 (44)
  No 74 (91) 19 (56)
Visibility of DSD‡
  Visible 12 (15) 17 (50)
  Partly hidden 57 (70) 17 (50)
  Hidden 12 (15)
Region
  Central Java 70 (86) 29 (85)
  Other provinces in Java 8 (10) 2 (6)
  Outside Java island 3 (4) 3 (9)
Ethnic
  Javanese 76 (94) 31 (91)
  Non-Javanese 5 (6) 3 (9)
Religion
  Islam 77 (95) 33 (97)
  Non-Islam 4 (5) 1 (3)
Residential setting
  Rural 45 (56) 15 (44)
  Suburban 24 (30) 11 (32)
  Urban 12 (15) 8 (24)
Highest education attained (Fathers§ / mothers§) (Adults)
  No formal education 9 (11) / 10 (13) 4 (12)
  Elementary school 27 (34) / 28 (35) 3 (9)
  High school 36 (45) / 36 (45) 23 (68)
  University 8 (10) / 6 (8) 4 (12)
Parents’ occupation (Fathers / mothers§) (Adults)
  Unemployed 0 / 44 (55) 13 (38)
  Labour 47 (59) / 22 (28) 9 (27)
  Self-employed 16 (20) / 6 (8) 4 (12)
  Staff 17 (21) /8 (10) 8 (24)
Data are presented in n (%).
*Treatment in most patients had been minimal, for instance, patients 
had taken glucocorticoid therapy for only a limited period or had 
undergone one surgical procedure for hypospadias correction when 
two or more procedures were recommended.14 25–27
†Social gender role change could be physician imposed, parent 
imposed or patient initiated.25
‡Visibility of DSD refer to all those aspects of physical and 
behavioural atypicality that cannot be hidden during social 
interaction. Concealable refers to physical atypicality that can be 
covered by clothes (partly hidden) and non-ambiguous phenotype 
(hidden).
§One father / mother missing for being deceased.
DSD, disorder of sex development.
subgroup analysis
Tables 4A and B summarise the comparisons across sex 
of rearing, treatment status, gender change history24 
and visibility of DSD conditions. In both boys and girls, 
children and adolescents experienced some degree of 
stigmatisation. Girls reported more stigmatisation due 
to atypical physical appearance or cross-gender role 
behaviour and had more emotional problems than boys 
(see table 4A; gender comparison). Women experienced 
more stigmatisation and had more emotional problems 
than men. Both men and women experienced some 
degree of verbal and behavioural reactions due to their 
DSD conditions (see table 4B; gender comparison).
Regardless of having received prior hormonal/surgical 
treatment for DSD, children and adolescents experienced 
stigmatisation and had emotional problems (see table 4A; 
treatment status comparison). However, untreated adults 
experienced more stigmatisation than treated adults (see 
table 4B; treatment status comparison).
Six youngsters and 15 adults were assigned female at 
birth but changed gender later in life.24 These patients 
experienced more stigmatisation than patients who kept 
their initial gender. Young people and adults experi-
enced more stigmatisation due to an ambiguous appear-
ance or cross-gender behaviour and had more emotional 
problems than youngsters who retained the initial sex of 
rearing (see tables 4A and B; social gender role change 
comparison). Adults who changed gender experienced 
more behavioural stigmatisation than adults who retained 
the gender assigned at birth (see table 4B; gender change 
history comparison).
Children and adolescents with visible ambiguity of the 
body experienced stigmatisation more frequently than 
patients who could conceal ambiguous characteristics 
(see table 4A; visibility of DSD comparison). Regard-
less of the visibility of DSD, children and adolescents 
reported emotional problems due to DSD. Adults with 
visible ambiguity of the body experienced more stigmati-
sation than adults who could conceal ambiguity; this was 
particularly seen in verbal and behavioural stigmatisation 
(see table 4B; visibility of DSD comparison).
Qualitative data
In text analyses, four themes were identified that gave 
insight into characteristics of social stigmatisation and 
related stress: (1) (correct, incorrect or lack of) knowl-
edge about DSD, (2) patients’ personality and related 
emotional and behavioural responses, (3) cultural norms 
and related social expectancies and (4) response from 
the community.
dIscussIOn
Our study revealed that atypical appearance of the geni-
tals and/or body is problematic.14 Stigmatisation was most 
prominent in patients with an atypical physical appear-
ance who could not hide their ambiguity, in untreated 
adult patients, in patients who changed their social gender 
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Table 3 Factor loadings after varimax rotation and Cronbach’s α of the SSS-DSD:
(A) Parental report (n=81)
Questions
Components
1* 2† 3‡ 4§
Stigma elicited by genital atypicality*
  01a. Can other people see that your child has genitals that are (slightly) different 
from that of other children?
0.60 0.44 0.07 −0.14
  01b. How stressful is this to you? 0.72 0.22 0.31 −0.09
  01c¶. Open-ended question: Can you tell us more about this?
  02a. Do you think that other people look at your child because of their atypical 
genitalia?
0.64 0.38 −0.05 0.19
  02b. How stressful is this to you? 0.73 0.13 0.17 0.21
  05a. Do other people speak negatively about your child because of their atypical 
genital or physical appearance?
0.65 −0.05 0.27 0.24
  05b. How stressful is this to you? 0.67 −0.10 0.34 0.14
  06a. Do people speak negatively about you because of your child? 0.76 −0.07 −0.18 0.13
  06b. How stressful is this to you? 0.73 −0.11 −0.17 0.15
  11a. Is your child called names or teased by other children because of their atypical 
genital or physical appearance?
0.40 0.03 0.24 0.55
  11b. How stressful is this to you? 0.41 0.02 0.44 0.49
Stigma elicited by physical atypicality or cross gender role behaviour†
  03a. Can other people see that your child has an atypical physical appearance? −0.09 0.76 0.07 0.35
  03b. How stressful is this to you? −0.14 0.52 0.18 0.48
  04a. Do you think that other people look at your child because of their atypical 
physical appearance?
0.39 0.67 −0.21 0.16
  04b. How stressful is this to you? 0.17 0.57 0.13 −0.01
  07a. Does your child show more cross-gender role behaviour compared with other 
children? For parents of daughters: Does your daughter prefer more masculine 
activities than other girls? For parents of sons: Does your son prefer more feminine 
activities compared with other boys?
−0.06 0.87 0.10 0.20
  07b. How stressful is this to you? −0.01 0.91 0.04 0.02
  08a. Do other people speak or behave negatively about your child because of their 
cross-gender role behaviour? (Daughters: masculine behaviour and interests? Sons: 
feminine behaviour and interests?)
0.11 0.44 −0.08 −0.05
Experiences with social exclusion‡
  09a. Do other people isolate your child because of atypical of their genital/physical 
appearance?
−0.03 0.34 0.76 0.19
  09b. How stressful is this to you? 0.04 0.24 0.85 0.03
  10a. Do other people isolate you because of your child? 0.17 −0.10 0.86 −0.13
  10b. How stressful is this to you? 0.21 −0.12 0.82 −0.14
  12a. Is your child isolated by other children because of their atypical genital or 
physical appearance?
−0.09 0.00 0.75 0.45
  12b. How stressful is this to you? 0.02 −0.08 0.88 0.22
Emotional reactions§
  13a. Does your child suffer from emotional problems because of their atypical 
genital or physical appearance?
0.26 0.00 −0.07 0.75
  13b. How stressful is this to you? 0.13 0.02 −0.03 0.82
  13 c. How frequent was your child sad? 0.09 0.06 −0.05 0.55
  13d. How frequent was your child depressed? 0.01 −0.01 0.07 0.82
  13g. How frequent was your child shy? −0.14 0.14 0.13 0.71
Continued
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(A) Parental report (n=81)
Questions
Components
1* 2† 3‡ 4§
  13h. How frequent was your child socially withdrawn? −0.11 0.34 0.13 0.61
  13e. How frequent was your child angry? 0.01 0.19 0.20 0.37
  13f. How frequent was your child aggressive? 0.12 0.05 0.28 0.24
  14. Are you worried about your child’s future? 0.20 −0.01 0.05 0.29
  15. Is it difficult for you to accept your child? 0.25 0.07 0.02 −0.12
*Stigmatisation due to genital ambiguity and stress evoked by such experiences (α=0.86).
†Stigmatisation due to atypical physical appearance or displayed cross-gender role behaviour and stress evoked by such experiences 
(α=0.84).
‡Social exclusion or isolation due to DSD and stress evoked by being rejected or isolated (α=0.88).
§Reported emotional problems seen in the child and parental stress evoked these emotional problems (α=0.85).
¶Each question 1–12 was followed by an open-ended question: Can you tell us more about this? Example?
SSS-DSD, Social Stigmatisation Scale–disorder of sex development.
Table 3 Continued 
and in girls and women. The more frequently they expe-
rienced DSD-related social stigma, the higher their stress. 
Patients who were able to hide features of body atypicality 
from others did not report less emotional problems than 
patients who had visible features of DSD. This suggests 
that fear and prevention of being stigmatised is as prob-
lematic as having experienced stigmatisation. From the 
qualitative data, we observed that a substantial number 
of patients withdrew themselves from social interactions, 
such as withdrawal from school and avoiding interaction 
with neighbours or community members. In Indonesia, 
those who show variant sex or gender development are 
often met with a hostile attitude; patients are humiliated 
and excluded.
Overall, many patients did not give high rates of expe-
rienced social stigmatisation; however, patients with 
atypical physical appearance are vulnerable to social 
stigmatisation. They indicated that stigmatisation was 
stressful, elicited negative emotions, hampered social 
participation and hence affected overall psychosocial 
well-being. Part of their social stigmatisation was related 
to lack of knowledge about DSD among patients them-
selves and among Indonesian laymen. We propose that 
stigmatisation can be prevented or reduced by educa-
tion. Similar to many other non-western countries, 
Indonesia has few well-trained medical psychologists 
available for counselling to help patients and parents 
cope with DSD. Once educated and supported, patients 
and parents can then educate their social network to 
improve their position in the community.30 In addition, 
educated patients and parents will be better able to 
decide which treatments are optimal for their partic-
ular circumstances.
Indonesia is a collective society in which procreation 
and progeny are highly valued. Some people with DSD 
cannot meet such expectations.14 24 25 Our findings are 
in line with previous studies reporting sexual distress, 
disclosure dilemmas and tendency to avoid romantic 
relationships among women with DSD.25 Women with 
DSD report a more vulnerable position than affected 
men in this culture. This may explain why we recruited 
more male patients (59%) than female patients (41%) 
for this study. This study includes 20 patients who 
underwent a female to male social gender change, 
4 patients changed gender in childhood, 16 of them 
initiated a change in adolescence or adulthood. Three 
patients had a 46, XX karyotype and CAH, 17 patients 
had a 46, XY karyotype.24
Progressive masculinisation may have induced gender 
dysphoria and instigated the wish to change gender, but 
ostracism may also contribute to this change.
Limited assessment of the construct validity of the 
SSS-DSD is a study limitation. Our study focused on the 
relationship between social stigmatisation and atypical 
appearance resulting from the delay of medical and 
surgical treatment. As no suitable measure was avail-
able, we developed one. In developing a measure, it is 
preferred to perform cross-validation studies in addi-
tion to PCA to assess construct validity more exten-
sively. Unfortunately, quantitative measures to assess 
different aspects of psychosocial well-being are unavail-
able in Indonesia and we were unable to perform such 
analyses.14 24 25
This study is relevant for patients with DSD who face 
delay in treatment due to poor understanding of their 
medical condition, inadequate laboratory support 
and lack of appropriate and affordable medications.21 
Although Western culture is individual centered and 
the demands to follow social norms (e.g., giving birth 
for women) are less stringent, Western patients with 
DSD have a vulnerable position in society too. Thus, 
the current results may be informative to patients 
and families outside of Indonesia. Ultimately, we aim 
to optimise patients’ psychosexual and psychosocial 
well-being and are searching for adaptations in clin-
ical management that are evidence-based, such as 
the reduction of stigmatisation of those affected by 
DSD.13
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Table 3 
(B) Adult report (n=34)
Questions
Components
1* 2† 3‡
Verbal stigmatisation*
  1a. Can other people see that you have genitalia that are (slightly) different from other men/
women?
0.63 0.03 0.10
  1b. How stressful is this to you? 0.62 0.36 0.42
  1c§. Open-ended question: Can you tell us more about this?
  2a. Do you think that other people look at you because of your atypical genitalia? 0.79 0.33 0.22
  2b. How stressful is this to you? 0.86 0.19 0.23
  4a. Do you think that other people look at you because of your atypical physical appearance? 0.71 −0.08 0.37
  4b. How stressful is this to you? 0.82 0.21 0.25
  5a. Do other people speak negatively about you because of your atypical genital or physical 
appearance?
0.75 0.08 −0.13
  5b. How stressful is this to you? 0.86 0.10 −0.05
7a. Do other people, including family members, speak or behave negatively about you because 
you show more cross-gender behaviour compared with others?
(For woman: Do you prefer more masculine activities compared with other women?
For man: do you prefer more feminine activities compared with other men?)
0.73 −0.27 0.12
7b. How stressful is this to you? 0.71 −0.23 0.12
Behavioural stigmatisation †
  3a. Can other people see that you have an atypical appearance? 0.08 0.65 0.41
  3b. How stressful is this to you? 0.43 0.55 0.23
  6a. Do you behave (slightly) differently from other men/women? 0.01 0.64 0.17
  6b. How stressful is this to you? 0.16 0.36 0.10
  9a. Do other people tease you or call you by funny names because of your atypical genital or 
physical appearance?
0.10 0.84 0.07
  9b. How stressful is this to you? 0.15 0.87 0.18
  10a. Do other people isolate/reject you because of your atypical genital or physical 
appearance?
−0.21 0.68 0.23
  10b. How stressful is this to you? −0.21 0.68 0.23
Emotional problems‡
  13a. Do you suffer from emotional problems because of your atypical genital/appearance? 0.31 0.40 0.75
  13b. How stressful is this to you? 0.31 0.37 0.75
  13c. How frequently were you sad? −0.06 0.20 0.94
  13d. How frequently were you depressed? 0.11 0.16 0.93
  13e. How frequently were you angry? 0.34 0.31 0.68
  13g. How frequently were you shy? 0.17 0.16 0.73
  13h. How frequently were you socially withdrawn? 0.11 0.14 0.71
  14. Are you worried about your future? 0.21 0.10 0.74
  15. Is it difficult for you to accept your condition? −0.02 0.20 0.75
*Verbal reaction received due to DSD conditions and the stress evoked by such experiences (α=0.92).
†Behavioural reaction received due to DSD conditions and the stress evoked by such experiences (α=0.85).
‡Reported emotional problem due to having DSD conditions (α=0.94).
§Each question 1–7, 9, 10 was followed by an open-ended question: Can you tell us more about this? Example?
SSS-DSD, Social Stigmatisation Scale–disorder of sex development.
cOnclusIOn
Patients with DSD, particularly those with an atyp-
ical appearance, are prone to stigmatisation. Such 
stigmatisation is stressful and leads to negative emotional 
reactions and social isolation. These findings support the 
assumption that an atypical physical appearance can be 
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harmful for psychosocial well-being. This may be particu-
larly true when the medical condition is not understood 
by the patient, the parents and members of the commu-
nity, as well as when the patient cannot make their 
own decisions regarding clinical management. Cultur-
ally sensitive education about DSD that is accessible to 
patients, families and the community would go a long 
way towards improving social acceptance and thereby the 
well-being of (young) people with DSD.
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